title: Sublingual immunotherapy: recent advances.
abstract: The practice of administering sublingual immunotherapy for respiratory allergy is gaining more and more diffusion worldwide as a consequence of the robust demonstration of clinical efficacy and safety provided by recent high-powered and well-designed studies, confirming for individual seasonal allergens the results of previous metanalyses in adult and pediatric populations. Preliminary evidence derives from recent rigorous trials on perennial allergens, like house dust mites, and specifically designed studies addressed the benefits on asthma. Emerging research suggests that SLIT may have a future role in other allergic conditions such as atopic dermatitis, food, latex and venom allergy. Efforts to develop a safer and more effective SLIT for inhalant allergens have led to the development of allergoids, recombinant allergens and formulations with adjuvants and substances targeting antigens to dendritic cells that possess a crucial role in initiating immune responses. The high degree of variation in the evaluation of clinical effects and immunological changes requires further studies to identify the candidate patients to SLIT and biomarkers of short and long term efficacy. Appropriate management strategies are urgently needed to overcome the barriers to SLIT compliance.
authors.affiliation: Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, Genoa, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Compalati
authors.forename: Fulvio
authors.initials: F
authors.lastname: Braido
authors.forename: Giorgio
authors.initials: G
authors.lastname: Walter Canonica
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000485:Allergens / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D017951:Antigen Presentation; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D010349:Patient Compliance; D011994:Recombinant Proteins / Q000235:genetics; D012130:Respiratory Hypersensitivity / Q000276:immunology* / Q000628:therapy*; D063729:Sublingual Immunotherapy / Q000379:methods* / Q000639:trends
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D011994:Recombinant Proteins